PFE
Pfizer Inc.
NYSE · USHealthcareDrug Manufacturers - General
$24.75-1.20%
Price as of Jul 20, 2026
PFE growth
Pfizer Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- +1.4%
- EBITDA
- -15.7%
- EBIT
- -13.7%
- EPS
- -5.7%
- Free cash flow
- -15.5%
- Operating cash flow
- -14.3%
Forward estimates
- Revenue
- -4.0%
- EBITDA
- +7.0%
- EPS
- +125.6%
Three-year CAGR
- Revenue
- -14.6%
- EBITDA
- -28.3%
- EBIT
- -25.6%
- Net income
- -37.2%
- EPS
- -37.6%
- Free cash flow
- -29.6%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.